Taken together, our study supports the idea that EGFR is a potential therapeutic target in NB and treating NB patients by ErbB family protein kinases inhibitors like afatinib alone or in combination with doxorubicin is a promising strategy. The gene discussed is EGFR; the disease is neuroblastoma.